European champions Chelsea completed the signing of highly-rated Belgium midfielder Eden Hazard from French club Lille yesterday.

Hazard’s move to Stamford Bridge had been expected since last week when he tweeted that he would be joining the Champions League winners and the transfer has now been finalised after the 21-year-old passed a medical.

“Chelsea Football Club is delighted to announce we have agreed terms with Lille for the transfer of Eden Hazard,” a statement on the club’s website confirmed.

“The 21-year-old Belgian international has agreed personal terms with the club and today passed a medical examination. He will join the club in July when the players return for pre-season training.”

The Blues have beaten Premier League rivals Manchester City and Manchester United for the signature of a player regarded as one of Europe’s brightest young stars.

Reports suggest Chelsea have paid £32 million to sign Hazard, which would make him the second most expensive player in Chelsea’s history behind £50 million striker Fernando Torres.

Meanwhile, it was also suggested yesterday that Porto forward Hulk had agreed terms with Chelsea on a four-year contract.

Hulk, who has been valued at £38m, has certainly seemed to pave the way for a potential transfer by hinting the time could be right for him to leave Portugal.

Asked what the future held for him, the 25-year-old said: “I will always continue to work hard and keep my feet on the ground, regardless of whether I stay at Porto.

“I have won many titles in the past four years at Porto, and I think that I have a great relationship with everyone.

“If the time has come to move on, I’ll do so with a good feeling.

“I’m sure that they will understand the motives behind my decision if I leave.”

Hulk, who is contracted to Porto until 2016, added: “The club and its fans will forever have a place in my heart.”

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.